Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Active not recruiting 3

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3Lymphoid 3Other hematologic neoplasm 1

Conditions

Wilms Tumor 6Lymphoma, Non-Hodgkin 6Rhabdoid Tumor 5Neuroectodermal Tumors, Primitive, Peripheral 5Neuroblastoma 5Medulloblastoma 5Histiocytosis, Langerhans-Cell 5Hepatoblastoma 5Glioma 5Ependymoma 5Sarcoma 4Rhabdomyosarcoma 4Osteosarcoma 4Lymphoma 4Central Nervous System Neoplasms 4Sarcoma, Ewing 3Multiple Myeloma 3Lung Neoplasms 3Breast Neoplasms 3Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neuroendocrine Tumors 2Malignant Solid Neoplasm 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Burkitt Lymphoma 2Xanthogranuloma, Juvenile 1Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1

Interventions

Dexamethasone 276Lenalidomide 154Bortezomib 152Cyclophosphamide 115Melphalan 107Calcium Dobesilate 107fludarabine phosphate 70carfilzomib 60pomalidomide 55Peripheral Blood Stem Cell Transplantation 53Whole-Body Irradiation 52Mycophenolic Acid 52Granulocyte Colony-Stimulating Factor 52Filgrastim 52daratumumab 45fludarabine 43Tacrolimus 41ixazomib 40Busulfan 40Thalidomide 36Cyclosporine 32dexamethasone acetate 26Stem Cell Transplantation 26Antilymphocyte Serum 25dexamethasone 21-phosphate 22plerixafor 20auricularum 20belantamab mafodotin 19Prednisone 19Etoposide 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Multiple Myeloma × X-Rays × Clear all
NCT06360575 2026-05-04

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
20 enrolled 10 charts
LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT06303167 2026-04-13

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
19 enrolled 10 charts
LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT06357975 2026-03-19

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
44 enrolled 10 charts
LymphoidPlasma cell

Lymphoma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡